PULMONARY ARTERIAL HYPERTENSION

This phase 2 study tests whether spironolactone, a drug already used for fluid retention, can improve exercise capacity and blood vessel function in people with pulmonary arterial hypertension (PAH). About 70 adults with PAH will receive either spironolactone or a placebo for 24 …

This long-term study follows people with pulmonary arterial hypertension (PAH) who previously took part in sotatercept trials. Sotatercept is a targeted therapy that aims to stop PAH from getting worse. Researchers will monitor safety, side effects, and how well patients tolerate…

This study offers continued access to the inhaled drug TPIP for people with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (PH-ILD) who have already completed a related study. Participants must have successfully finished prior …

This phase 3 trial is testing whether a once-daily inhaled medication called treprostinil palmitil can help adults with pulmonary arterial hypertension (PAH) walk farther. About 344 participants will receive either the drug or a placebo for 24 weeks. The main goal is to see if th…

This study tests whether implanted monitors can quickly show if a new PAH drug is working. About 40 adults with stable PAH will try two different approved drug plans while their heart and lung function are tracked. The goal is to see if this approach can help doctors choose the b…

This study tests whether the drug sotatercept can improve how well the lungs transfer oxygen in people with pulmonary arterial hypertension (PAH). Twenty-seven adults with PAH will receive the drug every 21 days for 29 weeks and undergo lung function tests, heart ultrasounds, and…

This study is testing a new medicine called PF-07868489 for people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lung arteries makes the heart work harder. The study is open-label, meaning everyone knows they are getting the drug, and it…

This study tests an experimental drug called IKT-001 in people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe and move. About 486 adults will receive either IKT-001 or a placebo to see if the drug improves b…

This Phase 2 trial tests an experimental drug called APL-9796 in 48 adults with pulmonary hypertension (high blood pressure in the lungs). The study aims to see if the drug is safe, tolerable, and effective. Participants receive injections under the skin, and researchers monitor …

This study is testing whether valsartan, a drug already used for high blood pressure, can help people with pulmonary arterial hypertension (PAH). Researchers will give 60 adults either valsartan or a placebo for 24 weeks to see if it improves how far they can walk in six minutes …

This study tests a drug called sotatercept in 42 children aged 1 to 18 who have pulmonary arterial hypertension (PAH), a serious lung condition that makes the heart work too hard. The drug is given as a shot every 3 weeks, and the main goal is to see if it is safe and how the bod…

This early-stage study tests a new way to use a heart-lung machine (ECMO) in 4 people waiting for a lung transplant who also have heart failure from high blood pressure in the lungs. The goal is to see if this approach can keep them alive and stable until they receive a transplan…

This early-stage study tests whether empagliflozin, a drug used for diabetes, can help people with pulmonary arterial hypertension (PAH). About 72 adults will take either the drug or a placebo daily for 12 weeks. Researchers will check if it lowers lung blood pressure and improve…

This early-stage trial tests the safety of a single inhaled dose of L608 in 32 healthy volunteers. L608 is a liposomal formulation designed to treat pulmonary arterial hypertension, a condition of high blood pressure in the lungs. The study compares different doses against a plac…

This early-stage trial tests whether transplanting gut bacteria from healthy donors, along with antibiotics and fiber, is safe for people with pulmonary arterial hypertension (PAH). 24 adults with PAH will be randomly assigned to receive either the bacteria capsules or a placebo.…

This study tests a new device for people with pulmonary hypertension, a condition where high blood pressure strains the heart. The device is implanted to help the heart pump better. About 30 adults with severe symptoms will take part to see if the device is safe and works well.

This study tests whether the drug sotatercept can improve right heart function in people with pulmonary arterial hypertension (PAH). PAH causes high blood pressure in the lungs, straining the right side of the heart. Sotatercept targets the underlying blood vessel changes, not ju…

This study tests whether a long-term rehabilitation program—combining home exercise and breathing muscle training—can improve clinical outcomes and heart-lung function in people with pulmonary arterial hypertension. About 104 adults with stable disease will be randomly assigned t…

This study tests whether a non-invasive device called electrical impedance tomography (EIT) can accurately diagnose pulmonary hypertension, a serious lung condition. Currently, diagnosis requires an invasive procedure called right heart catheterization. Researchers will compare E…

This study tests whether inhaling a special form of xenon gas during an MRI can help doctors see and measure blood vessel changes in the lungs of people with pulmonary arterial hypertension (PAH). The goal is to find a non-invasive way to diagnose different types of PAH and track…

This early-phase study tests whether a special PET scan tracer, 18F-fluoroglutamine, can detect pulmonary arterial hypertension (PAH) earlier and more accurately. PAH is a serious disease of the lung's blood vessels that often goes undiagnosed for years. The study will scan 71 ad…

This study tests whether a 12-week home-based exercise program, started soon after diagnosis, improves walking distance and quality of life in people with pulmonary hypertension. Forty participants will either exercise early or wait six months. The goal is to see if exercise plus…

This study tests whether a mobile health program can help adolescents with pulmonary arterial hypertension increase their daily step counts. About 50 teens aged 10-21 will use a Fitbit and receive coaching to boost activity over 12 weeks. The goal is to improve exercise and quali…

This study tests whether a 12-week home exercise program can improve exercise capacity and quality of life in 20 adults with pulmonary arterial hypertension (PAH). Participants receive guidance from a physiotherapist to do endurance and strength training at home. The main goal is…

This study looks at whether detailed heart scans (echocardiograms and MRIs) can improve how doctors predict short-term risks in people with a type of high blood pressure in the lungs (pulmonary arterial hypertension). Researchers will follow 50 adults for 6 months to see if addin…

This natural history study follows 270 adults with pulmonary arterial hypertension (PAH) and healthy volunteers to track how the disease changes over time. Researchers will use blood tests, heart and lung imaging, and a six-minute walk test to find new markers of disease severity…

This study examines why fat accumulates in the right ventricle of people with pulmonary arterial hypertension (PAH) and how it affects heart function and exercise ability. Researchers will use MRI and blood tests in 75 adults with PAH to track changes over time. The goal is to be…

This study follows 27 pregnant women living at high altitude in Bolivia and compares them to women at sea level. Researchers will use heart ultrasounds and blood tests to see how the body adapts to low oxygen levels during pregnancy. The goal is to better understand why some wome…

This study looks at why people with pulmonary arterial hypertension (PAH) lose muscle mass and how that affects their daily life and activity. Researchers will measure body composition, heart fat, diet, and physical function in 150 adults with PAH. No new treatment is being teste…

This study aims to find genes that make some people with congenital heart defects develop a serious lung condition called pulmonary arterial hypertension (PAH). Researchers will analyze DNA from blood samples of 21 patients with heart defects who also have PAH. The goal is to ide…

This study is collecting blood and other samples from 5,000 children and young adults (under 21) who are already taking certain medications as part of their regular care. The goal is to understand how these drugs move through and affect children's bodies, so doctors can prescribe…

This study aims to develop a noninvasive way to detect blood vessel changes in the lungs of people with Group 3 pulmonary hypertension (PH) using a special MRI technique. Researchers will compare MRI results with lung tissue from 30 patients awaiting lung transplant. The goal is …

This study is testing whether a special MRI using inhaled xenon gas can track how well the drug sotatercept repairs blood vessels in the lungs of people with pulmonary arterial hypertension (PAH). Fourteen adults with PAH will have xenon MRI scans before and after starting sotate…

This study is a national registry that collects information from 3,000 people with pulmonary hypertension (PH) treated at specialized centers across the U.S. Researchers will track how patients are diagnosed, treated, and how they do over time. The goal is to see if care follows …

This study looks at how genes may increase the risk of pulmonary hypertension (high blood pressure in the lungs). Researchers will collect health surveys and saliva samples from 10,000 adults in the US, both with and without the condition. The goal is to find genetic links that c…

This study looks at how long it takes for people in Brazil to get a correct diagnosis of pulmonary arterial hypertension (PAH), a rare and serious lung disease. Researchers will review medical records of about 139 adults diagnosed in the last five years to find out what causes de…

This study looks at what happens when people with pulmonary arterial hypertension (PAH) switch from one medication (ambrisentan) to another (bosentan). Researchers will track 121 adults to see if their risk level, symptoms, and side effects change after the switch. The goal is to…